Satsuma Pharmaceuticals, Inc. STSA
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 36.80M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -1.29
- Beta
- 0.10
- Short ratio
- 0.05
- Inst. own
- 57.90%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 11, 2023
- 50-d avg
- 0.991336
- 200-d avg
- 2.18
- 1y target
- 2.00
News
4 months ago prnewswire.com
Satsuma Pharmaceuticals Announces Presentation of Two Clinical Program Abstracts at the American Headache Society's 68th Annual Scientific Meeting
DURHAM, N.C., June 4, 2026 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing innovative treatments for people living with migraine, today announced that…
12 months ago prnewswire.com
Satsuma Pharmaceuticals and SNBL Announce Publication of Impression of Use and Satisfaction with STS101 (Dihydroergotamine Nasal Powder (Atzumi™)) in Headache
Results show that participant impression through 12 months of treatment indicate STS101 is perceived as favorable across multiple attributes. Exploratory Efficacy Endpoints showed that STS101…
1 year ago prnewswire.com
Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting
DURHAM, N.C. , June 19, 2025 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other…
1 year ago prnewswire.com
Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine
Atzumi™ (dihydroergotamine(DHE)) nasal powder is the first and only DHE nasal powder for the acute treatment of migraine with or without aura in adults in an easy-to-use, easy-to-carry device. Atzumi…
1 year ago prnewswire.com
Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDA Resubmission of STS101 for the Acute Treatment of Migraine With or Without Aura
DURHAM, N.C. , Nov. 26, 2024 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd.
2 years ago prnewswire.com
Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura
DURHAM, N.C. , Oct. 30, 2024 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd.
2 years ago prnewswire.com
Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs
Study shows the repeated long-term, as-needed use of STS101 for the acute treatment of a migraine attack demonstrated a favorable safety profile and was well tolerated. Exploratory Efficacy Endpoints…
2 years ago prnewswire.com
Satsuma Pharmaceuticals and SNBL Announce Five Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 66th Annual Scientific Meeting
DURHAM, N.C. , June 13, 2024 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug Administration for…
-
3 years ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
3 years ago benzinga.com
Why Universal Electronics Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Ibio Inc (NYSE: IBIO) shares rose 97% to $1.4787 after the company announced MUC16 as its latest immune-oncology target program.
3 years ago pennystocks.com
Best Penny Stocks To Buy Now? 7 Insider Picks In November
7 penny stock picks from insiders in November 2022 The post Best Penny Stocks To Buy Now? 7 Insider Picks In November appeared first on Penny Stocks to Buy, Picks, News and Information |…
3 years ago pennystocks.com
Penny Stocks To Buy: 7 Insider Picks For November 2022
Penny stocks to buy according to insiders in November 2022. The post Penny Stocks To Buy: 7 Insider Picks For November 2022 appeared first on Penny Stocks to Buy, Picks, News and Information |…
3 years ago investorplace.com
Why Is Satsuma Pharmaceuticals (STSA) Stock Down 80% Today?
The focus in the world of drugmakers is on Satsuma Pharmaceuticals (NASDAQ: STSA ) right now, but not in a good way. Specifically, the company's proposed treatment for migraine headaches didn't meet…
4 years ago globenewswire.com
Satsuma Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
South San Francisco, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)…
-
4 years ago benzinga.com
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
Gainers
4 years ago globenewswire.com
Satsuma Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
SOUTH SAN FRANCISCO, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal…
-
4 years ago benzinga.com
Stocks That Hit 52-Week Lows On Friday
On Friday, 111 companies set new 52-week lows.
4 years ago globenewswire.com
Satsuma Pharmaceuticals to Present at the Virtual 11th Annual SVB Leerink Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)…
5 years ago globenewswire.com
Satsuma Pharmaceuticals Announces the Appointment of Mutya Harsch to its Board of Directors
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)…
5 years ago globenewswire.com
Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)…
5 years ago globenewswire.com
Satsuma Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)…
5 years ago globenewswire.com
Satsuma Pharmaceuticals Reports Second Quarter 2021 Financial Results and Recent Business Highlights
- Initiated STS101 SUMMIT Phase 3 efficacy trial; topline results expected second half 2022-
5 years ago globenewswire.com
Satsuma Pharmaceuticals to Present at SVB Leerink's CNS Forum
SOUTH SAN FRANCISCO, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE)…
5 years ago pulse2.com
STSA Stock Price Increases Over 15% Pre-Market: Why It Happened
The stock price of Satsuma Pharmaceuticals Inc (NASDAQ: STSA) increased by over 15% pre-market. This is why it happened.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Lows On Thursday
Before 10 a.m. ET Thursday, 132 stocks made new 52-week lows.
-
6 years ago benzinga.com
56 Biggest Movers From Friday
Gainers Nano-X Imaging Ltd. (NASDAQ: NNOX) shares gained 32.9% to close at $64.19. Nano X Imaging recently announced it has signed an agreement with SPI Medical for the deployment of 630 Nanox.ARC…
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Tuesday
On Tuesday, 154 stocks made new 52-week highs.
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Monday
Stocks That Hit 52-Week Highs On Monday
-
6 years ago benzinga.com
Stocks That Hit 52-Week Highs On Wednesday
Stocks That Hit 52-Week Highs On Wednesday